Litigation Details for Biofer S.p.A. v. Vifor (International) AG. (E.D.N.Y 2022)
✉ Email this page to a colleague
Biofer S.p.A. v. Vifor (International) AG. (E.D.N.Y 2022)
| Docket | ⤷ Sign Up | Date Filed | 2022-04-15 |
| Court | District Court, E.D. New York | Date Terminated | 2024-08-30 |
| Cause | 35:271 Patent Infringement | Assigned To | Ann Marie Donnelly |
| Jury Demand | Plaintiff | Referred To | Sanket J. Bulsara |
| Patents | 7,612,109; 7,754,702; 8,895,612; 9,376,505 | ||
| Firms | Greenberg Traurig LLP, Ip Department; Rhoads Legal Group PC | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Biofer S.p.A. v. Vifor (International) AG.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Biofer S.p.A. v. Vifor (International) AG. (E.D.N.Y 2022)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2023-09-15 | 90 | Amended Complaint | United States Patent Nos. 7,612,109 (“the ’109 Patent”); 7,754,702 (“the ’702 Patent”); 8,895,612 (“…of New York and is the licensee of U.S. Patent No. 7,612,109.” (Id.) In Vifor’s PTE Request, Vifor further…United States Patent Nos. 8,759,320 (“the ’320 Patent” or “the Asserted Patent”) under the Patent Laws of …the ’109 Patent also appear in the ’505 Patent and ’321 Patent, and citations to the ’109 Patent are representative…(“the ’612 Patent”); 9,376,505 (“the ’505 Patent”), and 11,123,321 (“the ’321 Patent”) (collectively, | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
